Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma
Cells · 17.06.2026 · 15 (12) · 1099
DOI: 10.3390/cells15121099 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 17.06.2026. Verfasst von John W Figg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Preston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32610, USA. Hauptthemen laut MEDLINE: Glioblastoma, Myeloid-Derived Suppressor Cells, Cell Movement, Brain Neoplasms. Die Arbeit nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Myeloid-derived suppressor cells (MDSCs) are a class of immature, heterogenous, and functionally immunosuppressive myeloid progenitors that are expanded in malignant disease including glioblastoma (GBM). Extensive preclinical evaluation of GBM has revealed that MDSCs express multiple different chemokine and cytokine receptors that facilitate their entry, infiltration, expansion and immunosuppression of antitumor immunity in the tumor microenvironment. Additionally, translational investigation of approaches that target MDSCs directly or indirectly through immune remodeling has yielded promising effects that are under clinical trial investigation. Given the immunosuppressive phenotype of high-grade gliomas like GBM, the removal of MDSCs represents a clinically relevant strategy to enhance immune responses against neoplastic cells. In this review, we provide a comprehensive summary of MDSCs in GBM, emphasizing clinical observations and large-scale multi-omics studies that position MDSCs at the nexus of GBM immunosuppression. Next, we provide detailed coverage of multiple chemokines, cytokines, and growth factors that are relevant to MDSC migration, survival and expansion in GBM along with commentary on the associated receptors. Lastly, we discuss therapeutic approaches that directly target MDSCs as a strategy to improve immune responses against malignant brains and observations on the changes to MDSCs in the tumor microenvironment after immunotherapy. Our review serves as a valuable resource for the neuro-oncology research space, updating scientists and clinicians on a cell central to the biology and therapeutic targeting of GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Preston A. Wells Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, University of Florida, Gainesville, FL 32610, USA.
ORCID-Profile: John W Figg, Caitland Love, Dan Jin
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Figg, J. W., Love, C., West, I., Jin, D., Engelbart, M., Ware, D., Bessey, R., & Flores, C. T. (2026). Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma. Cells, 15(12), 1099. https://doi.org/10.3390/cells15121099
Vancouver
Figg JW, Love C, West I, Jin D, Engelbart M, Ware D, et al. Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma. Cells. 2026;15(12):1099. doi:10.3390/cells15121099
BibTeX
@article{Figg2026,
author = {Figg, John W and Love, Caitland and West, Illeana and Jin, Dan and Engelbart, Mia and Ware, Dorothy and Bessey, Rachael and Flores, Catherine T},
title = {Myeloid-Derived Suppressor Cells: Function, Migration, and Therapeutic Opportunities in Glioblastoma},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1099},
doi = {10.3390/cells15121099}
}
EUVIMED